Background
==========

Clopidogrel, which can inhibit adenosine diphosphate (ADP)-induced platelet aggregation, has been applied to the prevention of atherothrombotic events for over 15 years \[[@b1-medscimonit-23-3824]\]. The variability in clopidogrel response is associated with environmental and genetic factors \[[@b2-medscimonit-23-3824]\]. Although clopidogrel has been widely used in patients with ischemic stroke, decreased metabolic activation of clopidogrel still occurs because of genetic variations in CYP2C19. The stent thrombosis risk in patients carrying a CYP2C19 loss-of-function allele appears to be similarly elevated across stable and unstable patient populations, regardless of elective or urgent PCI, or treatment with bare-metal or drug-eluting stents \[[@b3-medscimonit-23-3824],[@b4-medscimonit-23-3824]\]. Many factors can influence the response of patients to clopidogrel therapy, including age, smoking, diabetes, drug interactions, and genetics \[[@b5-medscimonit-23-3824],[@b6-medscimonit-23-3824]\].

As a pro-drug, clopidogrel requires metabolic activation by the hepatic cytochrome (CYP) P450 system, which includes CYP2C19, CYP2C9, CYP2B6, CYP3A4, and CY P3A5 \[[@b2-medscimonit-23-3824]\]. Specifically, the polymorphisms of CYP2C19 are thought to play an important role in this poor clopidogrel response \[[@b7-medscimonit-23-3824]\]. Individuals carrying at least 1 loss-of-function allele (either \*2 or \*3) of the CYP2C19 gene demonstrate reduced active clopidogrel metabolites and suppressed anti-platelet activity \[[@b8-medscimonit-23-3824]\]. The 2009 Japanese Guidelines for the Management of Anticoagulant and Anti-Platelet Therapy in Cardiovascular Disease recommend the use of anti-platelet agents for preventing reinfarction following percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) \[[@b9-medscimonit-23-3824]\]. The presence of at least 1 reduced-function CYP2C19 allele was associated with increased risk of major adverse cardiovascular events (MACE), particularly stent thrombosis, in clopidogrel-treated patients \[[@b10-medscimonit-23-3824]\]. For this reason, CYP2C19 genetic testing has been proposed before starting clopidogrel therapy to identify patients likely to show reduced anti-platelet activity \[[@b11-medscimonit-23-3824]\].

Ticagrelor (formerly developed as AZD6140) is a first-in-class anti-platelet agent chemically known as a cyclopentyl triazolopyrimidine, with distinguishing properties from that of the pyridines like ticlopidine, clopidogrel, or prasugrel. Ticagrelor, a novel oral P2Y~12~ antagonist that does not undergo bio-transformation to active metabolites, has many favorable pharmacological dynamic characteristics, including rapid onset of action and reversibility, and consistent inhibition of platelet function \[[@b12-medscimonit-23-3824]\]. Some studies have shown a higher prevalence of on-treatment platelet re-activity, but with a similar thrombotic event rate after PCI in East Asian patients compared with white patients \[[@b13-medscimonit-23-3824]\].

Tongxinluo in capsule form is a compound prescription formulated according to the meridian theory of traditional Chinese medicine and approved in 1996 by the State Food and Drug Administration of China for treatment of angina pectoris and ischemic stroke \[[@b13-medscimonit-23-3824]\]. Pharmacological research has revealed that treatment with tongxinluo capsule has a variety of therapeutic effects, such as improvement of endothelial cell function, lipid lowering, anti-inflammation, anti-apoptosis, and enhancement of angiogenesis \[[@b14-medscimonit-23-3824]\].

Our study was conducted to evaluate the influences of dual-dose clopidogrel, clopidogrel combined with tongxinluo, and ticagrelor on patients with CYP2C19 gene polymorphisms after PCI at 3, 6, and 12 months.

Material and Methods
====================

Study design and patient population
-----------------------------------

Overall, 458 patients with cardiovascular disease who received PCI treatment from June 2012 to June 2014 at Department of Cardiology, Hebei Provincial People 's Hospital were selected. Patients were included in the study according to the following criteria: (1) age \>18 years; (2) diagnosis of coronary artery disease by coronary angiography in parallel PCI; (3) carry at least 1 CYP2C19 \* 2 allele by genotyping assays; (4) PCI patients were treated with clopidogrel for anti-platelet therapy; (5) patients without other cardiovascular disease. Exclusion criteria were: (1) recent history of severe organ damage or surgery; (2) upper gastrointestinal ulcer or bleeding; (3) currently suffering from congenital heart disease, cardiomyopathy, myocarditis, peripheral vascular disease, or and infective endocarditis; (4) liver and kidney function was severely abnormal; (5) blood coagulation disorders; (6) cancer patients; (7) history of allergies to aspirin and clopidogrel; (8) took tongxinluo or ticagrelor before enrolment; (9) received warfarin sodium, propranolol, cimetidine, any kind of antibiotics or anti-fungal drugs, antidepressants, benzodiazepines, or anti-psychotics.

Patients were given aspirin 300 mg for the first time after admission, followed by 100 mg/day and clopidogrel 75 mg/day for routine treatment. Among the 458 patients with coronary artery disease who received successful PCI, 231 patients had at least 1 CYP2C19\*2 allele. According to the inclusion and exclusion criteria and the patients, 212 patients were eventually selected and divided into the standard anti-platelet group (regular-dose clopidogrel group) (RCG) of 46 patients (75 mg/day, 12 months), the double-dose clopidogrel group (DCG) of 50 cases (150 mg/day for 1 month, then 75 mg/day), the clopidogrel combined with tongxinluo group (CTG) of 59 cases (0.26 g/tablet, 4×3/day, 3 months), and the ticagrelor group (TG) of 57 cases (90 mg×2/day, 12 months). The differences in platelet activity and the occurrence of MACE events in the 4 groups of patients at different follow-up times were analyzed and compared.

DNA extraction
--------------

Blood samples were collected from all individuals into EDTA tubes. Genomic DNA was extracted from whole blood using the MagNA Pure automated extraction system according to the manufacturer's instructions. The quantity and purity of the extracted DNA was assessed with a Nanodrop ND-1000 device. DNA concentration was subsequently adjusted to a concentration of 5 ng/ml. The samples were stored at −80°C.

CYP2C19\*2 detection
--------------------

Genomic DNA from whole blood was isolated using a QIAamp^®^ DNA Blood Mini Kit (QIAGEN, Les Ulis, France) according to the manufacturer's instructions. CYP2C19 genotyping for rs4244285 G\>A (CYP2C19\*2) was carried out by Taq Man^®^ allelic discrimination assays on an ABI PRISM 7000 Sequence Detection System (Applied Biosystems). Direct sequencing was used to validate internal quality controls corresponding to genomic DNA of each genotype.

Platelet inhibition rate and MA-ADP detection
---------------------------------------------

A TEG thromboelastograph was used for platelet inhibition rate detection. TEG software automatically calculated the platelet inhibition rate and the ADP-induced maximum clot strength (MA-ADP) according to the detection results. ADP receptor inhibition rate \<20% is defined as clopidogrel resistance.

Efficacy
--------

MACE was defined as a composite of cardiovascular death, non-fatal MI, and non-fatal ischemic stroke. For the purpose of this report, efficacy outcomes included MACE occurring through 12 months, cardiovascular death, non-fatal myocardial infarction (MI), recurrence of unstable angina, target vessel reconstruction, revascularization, and stent thrombosis.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS 13.0. The measurement data are expressed by mean ± standard deviation (SD). Differences between 2 groups were compared by *t* test, differences between multiple groups were compared by ANOVA, and the LSD *t* test was used to compare 2 groups among multiple groups. Count data is expressed as frequency, rate of comparison using the chi-square test or Fisher exact probability method. Kaplan-Meier method was used to draw the curve of adverse cardiovascular events during follow-up.

Results
=======

Clinicopathological characteristics of patients
-----------------------------------------------

The patients with CYP2C19\*1\*2 or CYP2C19\*2\*2 were enrolled, and were divided into 4 groups: (1) regular-dose clopidogrel group; (2) double-dose clopidogrel group, (3) tongxinluo capsule combined with regular anti-platelet therapy group, and (4) ticagrelor group. The baseline information and clinicopathological characteristics of the 4 groups of patients are summarized in [Table 1](#t1-medscimonit-23-3824){ref-type="table"}. There were no significant differences in age, sex, BMI, smoking status, hypertension, diabetes, dyslipidemia, number of stentings, platelet count, or ejection fraction among the 4 groups (*P*\>0.05). During follow-up study, the drug use among patients had no significant differences (*P*\>0.05).

The platelet inhibition rate in the 4 groups of patients varied during follow-up
--------------------------------------------------------------------------------

At 3 days after PCI, the platelet inhibition rates of the double-dose clopidogrel group, the clopidogrel combined with tongxinluo group, and the ticagrelor group were lower than that of the standard anti-platelet therapy group. The 4 groups of patients had different platelet inhibition rates during the follow-up study. Using the repeated measurement of variance analysis, we found that the platelet inhibition rates were different at different time points (*F*=106.588, *P*\<0.01) ([Table 2](#t2-medscimonit-23-3824){ref-type="table"}), and there was interaction between time and grouping. The inhibition rates of platelets were analyzed at different time points. The results showed that the platelet inhibition rate of the double-dose clopidogrel group, the tongxinluo group, and the ticagrelor group was higher than that of the standard anti-platelet group at 1 month after the operation (*P*\<0.05). After 6 months, the platelet inhibition rate in the ticagrelor group was higher than in the other 3 groups (*P*\<0.05); however, the double-dose clopidogrel group and combined with tongxinluo group were lower than the standard anti-platelet group (*P*\<0.05). At 12 months after surgery, statistical results were similar to those at 6 months, and the ticagrelor group had the highest platelet inhibition rate. However, we found that although the platelet inhibition rate of patients in the ticagrelor group was always at a high level, the platelet inhibition rate was still reduced with prolonged administration ([Figure 1](#f1-medscimonit-23-3824){ref-type="fig"}). The combined with tongxinluo group achieved the maximum platelet inhibition rate at 3 months, while the double-dose clopidogrel group and ticagrelor group reached the maximum in the first month.

Occurrence of MACE in patients from the 4 groups at 12-month follow-up
----------------------------------------------------------------------

After 12 months of follow-up, the incidence of adverse cardiovascular events in the double-dose clopidogrel group, the combined tongxinluo group, and the ticagrelor group was significantly lower than that in the standard anti-platelet group ([Figure 2](#f2-medscimonit-23-3824){ref-type="fig"}, [Table 3](#t3-medscimonit-23-3824){ref-type="table"}), but single occurrence of adverse cardiovascular events such as MACE composite end point, cardiac death, non-fatal myocardial infarction, and TVR were not significantly different in any group ([Figure 3](#f3-medscimonit-23-3824){ref-type="fig"}, [Table 3](#t3-medscimonit-23-3824){ref-type="table"}).

Occurrence of bleeding events in patients from the 4 groups after 12-month follow-up
------------------------------------------------------------------------------------

All patients were followed up for 12 months, and we found that all groups of patients had mild bleeding, but no major bleeding occurred. The incidence of bleeding in the ticagrelor group was higher than in the other 3 group, and the difference was statistically significant ([Table 4](#t4-medscimonit-23-3824){ref-type="table"}).

Discussion
==========

In this study, patients after intervention received 1 of 4 therapeutic regimens: the standard anti-platelet group, clopidogrel double-dose group, combined with tongxinluo group, and ticagrelor group. After a 12-month follow-up, we observed the platelet aggregation rate of patients at 1, 3, 6, and 12 months and MACE events at 12 months postoperatively. The results showed that the platelet inhibition rates of the clopidogrel double-dose group, combined with tongxinluo group, and ticagrelor group were all higher than in the standard anti-platelet group after using the adjustment program. This suggests that patients in the clopidogrel double-dose group, combined with tongxinluo group, and ticagrelor group had lower odds of adverse cardiovascular events than those in the standard anti-platelet group. Total MACE events were lower in the standard anti-platelet group than in the other 3 groups. However, any of these regimens can cause mild bleeding.

Von Beckerath et al. \[[@b15-medscimonit-23-3824]\] showed that clopidogrel 75 mg/day at a maintenance dose of 150 mg/day was more effective in inhibiting ADP-induced platelet proliferation after PCI. Aradi et al. \[[@b16-medscimonit-23-3824]\] administered clopidogrel 150 mg/day and 75 mg/day for 30 days and found that 150 mg/day of clopidogrel can effectively reduce the stability of patients with stable angina pectoris ischemic and thrombotic events. Tongxinluo capsule is a Chinese herbal compound preparation. Studies have shown that dual anti-platelet combined with the Naoxintong not only inhibits platelet aggregation and significantly reduces intracoronary microthrombosis, but also reduces the risk of bleeding. Ticagrelor is an ADP receptor antagonist that reversibly binds to the ADP receptor. Wallentin et al. \[[@b17-medscimonit-23-3824]\] compared the efficacy and safety of ticagrelor and clopidogrel, and found that the incidence of combined end points was significantly lower in the tegrellozin group than in the clopidogrel group, whereas there was no significant difference between the 2 groups in total bleeding events. Gurbel et al. \[[@b18-medscimonit-23-3824]\] found that in clopidogrel nonresponders, in the switch to ticagrelor, the platelet aggregation rate was significantly reduced, but when switching from ticagrelor to clopidogrel the platelet aggregation rate was significantly higher. This study is consistent with some previous non-Chinese studies, suggesting that patients with clopidogrel resistance can choose from among double-dose clopidogrel, clopidogrel combined with tongxinluo, or replacement of ticagrelor to relieve clopidogrel resistance.

The main components of tongxinluo capsule are ginseng, Quanjie, centipede, leech, soil insects, cicada skin, borneol, red peony, and other drugs. Modern pharmacological research found that tongxinluo capsules contains leeches, Quanjie, centipede, Eupolyphaga, and other insects. Its effects include hirudin effect, inhibition of extracellular matrix synthesis and secretion of inflammatory cells, and inflammatory cell aggregation. Its lumbrokinase-like effect can directly dissolve fibrin, but can also to activate plasminogen as plasmin, and thus the indirect dissolution of fibrin, with anti-platelet aggregation and anti-thrombotic effect. Ginseng stems and leaves, reed head, and fruit saponins can promote myocardial DNA synthesis in neonatal rats, and saponins promote prostaglandin l2 synthesis and inhibition of thromboxane formation. Red peony expands the coronary artery, inhibits platelet aggregation and smooth muscle hyperplasia, lowers blood lipids and lipid peroxidation, and protects vascular endothelial cells. Borneol can increase the plasma concentration of other drugs, promote gastrointestinal absorption, dilate the coronary artery, and slow the heart rate, thereby relieving angina. In addition, tongxinluo capsules can increase the expression of thrombin III, tissue plasminogen activator (t-PA), fibrinogen (FIB), and plasminogen activator inhibitor (Pal-1), thus regulating the balance of coagulation and fibrinolysis in patients with stent implantation, decreases the levels of ET-1, and increase NO and calcitonin gene-related peptide (CGRP). Studies have confirmed that tongxinluo capsules can reduce the incidence of clopidogrel resistance in ACS patients, but whether CYP2C19 loss-of-allele variants can slow platelet function resistance, thereby reducing the incidence of cardiovascular events, needs further study and observation.

In addition to genetic factors, patient compliance, drug interactions, left ventricular function, increases in other platelet activation pathways, and increased ADP release all can contribute to the recurrence of adverse cardiovascular events in patients after PCI. Therefore, we should look for more patients with PCI after the recurrence of adverse cardiovascular events, and, through the early identification of CYP2C19\*2 carriers, adjust the dose, combined with other anti-platelet drugs or replacement of ticagrelor to improve the efficacy of anti-platelet therapy and reduce the incidence of ischemic events after PCI.

Conclusions
===========

Our data suggest that the effects of double-dose clopidogrel, clopidogrel combined with tongxinluo, and ticagrelor in inhibiting platelet aggregation was better than the regular-dose standard anti-platelet therapy, and ticagrelor was the best. The total incidence of MACE was much lower in the double-dose clopidogrel group, clopidogrel combined with tongxinluo group, and ticagrelor group, while the incidence of hemorrhage in the ticagrelor group was higher. Adjusting the dose or combining other drugs could improve the efficacy of anti-platelet therapy and reduce the incidence of ischemic events after PCI.
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###### 

Comparison of baseline data between patients from 3 groups with different metabolic syndrome.

  General features                   Regular dose of Clopidogrel group (n=46)   Double dose of Clopidogrel group (n=50)   Combined with Tongxinluo group (n=59)   Ticagrelor group (n=57)   *F*     *P*
  ---------------------------------- ------------------------------------------ ----------------------------------------- --------------------------------------- ------------------------- ------- -------
  Age                                59.61±9.58                                 59.84±10.01                               58.92±10.83                             60.79±9.18                0.348   0.790
  Gender                             29                                         31                                        35                                      34                        0.213   0.975
  Smoking status                     15                                         19                                        21                                      20                        0.308   0.959
  Hypertension                       25                                         28                                        34                                      32                        0.113   0.990
  Diabetes                           11                                         15                                        19                                      18                        1.013   0.807
  Dyslipidemia                       11                                         13                                        18                                      16                        0.630   0.889
  BMI (kg/m^2^)                      25.31±3.27                                 26.16±2.94                                25.75±3.19                              25.83±3.57                0.441   0.648
  Number of diseased blood vessels   1.68±0.58                                  1.61±0.64                                 1.66±0.72                               1.67±0.65                 0.281   0.839
  Number of stenting                 1.44±0.68                                  1.47±0.79                                 1.51±0.75                               1.46±0.72                 0.361   0.781
  Platelet count                     210.57±56.43                               214.02±55.46                              209.79±58.59                            212.63±56.49              0.061   0.980
  Ejection fraction (%)              61.84±9.21                                 59.94±10.68                               60.92±11.06                             61.02±9.48                0.529   0.663
  ACEI/ARB                           33                                         36                                        41                                      39                        0.230   0.973
  CCB                                13                                         15                                        21                                      18                        0.732   0.866
  PPI                                41                                         44                                        53                                      51                        0.103   0.991
  β-blocker                          30                                         35                                        42                                      38                        0.566   0.904

###### 

The change of platelet inhibition rate of patients from 4 groups during follow-up.

                                                      3 days (%)                                                        1 month (%)                                                                                                                                                                3 month (%)                                                                                                            6 month (%)                                                                                                                                                                12 month (%)
  --------------------------------------------------- ----------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Regular dose of Clopidogrel group (n=46)            50.16±11.21                                                       48.15±10.35                                                                                                                                                                48.27±11.45                                                                                                            47.58±11.34                                                                                                                                                                46.76±10.61
  Double dose of Clopidogrel group (n=50)             31.02±12.04[\*](#tfn1-medscimonit-23-3824){ref-type="table-fn"}   67.02±10.04[\*](#tfn1-medscimonit-23-3824){ref-type="table-fn"},[&](#tfn3-medscimonit-23-3824){ref-type="table-fn"}                                                        31.96±11.69[\*](#tfn1-medscimonit-23-3824){ref-type="table-fn"}                                                        32.24±10.31[\*](#tfn1-medscimonit-23-3824){ref-type="table-fn"}                                                                                                            31.23±9.29[\*](#tfn1-medscimonit-23-3824){ref-type="table-fn"}
  Clopidogrel combined with Tongxinluo group (n=59)   29.66±11.67[\*](#tfn1-medscimonit-23-3824){ref-type="table-fn"}   58.67±13.71[\*](#tfn1-medscimonit-23-3824){ref-type="table-fn"},[\#](#tfn2-medscimonit-23-3824){ref-type="table-fn"}                                                       64.74±19.37[\*](#tfn1-medscimonit-23-3824){ref-type="table-fn"},[\#](#tfn2-medscimonit-23-3824){ref-type="table-fn"}   31.81±11.02[\*](#tfn1-medscimonit-23-3824){ref-type="table-fn"}                                                                                                            30.97±10.43[\*](#tfn1-medscimonit-23-3824){ref-type="table-fn"}
  Ticagrelor group (n=57)                             30.84±10.87[\*](#tfn1-medscimonit-23-3824){ref-type="table-fn"}   71.86±20.87[\*](#tfn1-medscimonit-23-3824){ref-type="table-fn"},[\#](#tfn2-medscimonit-23-3824){ref-type="table-fn"},[&](#tfn3-medscimonit-23-3824){ref-type="table-fn"}   69.03±19.25[\*](#tfn1-medscimonit-23-3824){ref-type="table-fn"},[\#](#tfn2-medscimonit-23-3824){ref-type="table-fn"}   62.86±16.94[\*](#tfn1-medscimonit-23-3824){ref-type="table-fn"},[\#](#tfn2-medscimonit-23-3824){ref-type="table-fn"},[&](#tfn3-medscimonit-23-3824){ref-type="table-fn"}   54.76±15.64[\*](#tfn1-medscimonit-23-3824){ref-type="table-fn"},[\#](#tfn2-medscimonit-23-3824){ref-type="table-fn"},[&](#tfn3-medscimonit-23-3824){ref-type="table-fn"}
  *F*                                                 35.639                                                            74.171                                                                                                                                                                     83.734                                                                                                                 81.323                                                                                                                                                                     57.708
  *P*                                                 \<0.001                                                           \<0.001                                                                                                                                                                    \<0.001                                                                                                                \<0.001                                                                                                                                                                    \<0.001

*P*\<0.05 compared with regular dose of clopidogrel group;

*P*\<0.05 compared with double dose of clopidogrel group;

*P*\<0.05 compared with Clopidogrel combined with Tongxinluo group.

###### 

Occurrence of MACE in patients from 4 groups after followed for 12 months.

  End event                             Regular dose of Clopidogrel group (n=46)   Double dose of Clopidogrel group (n=50)                 Combined with Tongxinluo group (n=59)                   Ticagrelor group (n=57)                                 *F*      *P*
  ------------------------------------- ------------------------------------------ ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- -------- -------
  In-stent restenosis/ thrombosis       2                                          0                                                       1                                                       1                                                       2.264    0.537
  TVR                                   2                                          1                                                       0                                                       0                                                       3.618    0.095
  UA                                    4                                          2                                                       1                                                       1                                                       3.732    0.285
  Non-fatal myocardial infarction       2                                          1                                                       1                                                       0                                                       2.526    0.415
  Cardiac death                         1                                          0                                                       0                                                       0                                                       3.122    0.217
  MACE composite endpoint               2                                          0                                                       1                                                       0                                                       3.287    0.207
  Total adverse cardiovascular events   14                                         4[\*](#tfn4-medscimonit-23-3824){ref-type="table-fn"}   6[\*](#tfn4-medscimonit-23-3824){ref-type="table-fn"}   3[\*](#tfn4-medscimonit-23-3824){ref-type="table-fn"}   14.339   0.002

*P*\<0.01 compared with regular dose of Clopidogrel group.

###### 

Occurrence of bleeding events in patients from 4 groups after followed for 12 months.

                    Regular dose of Clopidogrel group (n=46)                Double dose of Clopidogrel group (n=50)                 Clopidogrel combined with Tongxinluo group (n=59)       Ticagrelor group (n=57)                                                                                       *F*      *P*
  ----------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- -------- -------
  Bleeding events   1[\#](#tfn6-medscimonit-23-3824){ref-type="table-fn"}   5[\*](#tfn5-medscimonit-23-3824){ref-type="table-fn"}   4[\*](#tfn5-medscimonit-23-3824){ref-type="table-fn"}   11[\*](#tfn5-medscimonit-23-3824){ref-type="table-fn"},[\#](#tfn6-medscimonit-23-3824){ref-type="table-fn"}   11.272   0.008
  Severe bleeding   0                                                       0                                                       0                                                       0                                                                                                             /        /
  Mild bleeding     1[\#](#tfn6-medscimonit-23-3824){ref-type="table-fn"}   5[\*](#tfn5-medscimonit-23-3824){ref-type="table-fn"}   4[\*](#tfn5-medscimonit-23-3824){ref-type="table-fn"}   11[\*](#tfn5-medscimonit-23-3824){ref-type="table-fn"},[\#](#tfn6-medscimonit-23-3824){ref-type="table-fn"}   11.272   0.008

*P*\<0.01 compared with regular dose of Clopidogrel group;

*P*\<0.01 compared with Clopidogrel combined with Tongxinluo group.
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